Date Item Type Full Text Status

Article

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications. (2018) Diana Gorog

Point-of-care Platelet Function Tests: Relevance to Arterial Thrombosis and Opportunities for Improvement. (2020) Diana Gorog and Richard Becker

MINOCA presenting with STEMI – incidence, aetiology and outcome in a contemporaneous cohort. (2019) Ying X. Gue, Natasha Corballis, Alisdair Ryding, Juan Carlos Kaski and Diana Gorog

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. (2019) Ying X Gue, Rahim Kanji, David M Wellsted, Manivannan Srinivasan, Solange Wyatt and Diana A Gorog

Incidence of thrombotic complications in COVID-19. (2021) William Jenner and Diana Gorog

Thrombotic complications in 2,928 patients with COVID-19 treated in intensive care: a systematic review. (2021) William Jenner, Rahim Kanji, Saeed Mirsadraee, Ying X. Gue, Susanna Price, Sanjay Prasad and Diana Gorog

Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis. (2017) Maria Niespialowska-Steuden, Vias Markides, Mohamed Farag, David Jones, Wajid Hussain, Tom Wong and Diana A Gorog

PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. (2014) G. Rosser, P. Tricoci, D. Morrow, C. Christopoulos, M. Niespialowska-Steuden, Robert Kozarski, R. Wilcox and Diana Gorog

Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture. (2019) Nikolaos Spinthakis, Ying Gue, Mohamed Farag, Guogang Ren, Manivannan Srinivasan, Anwar Baydoun and Diana A Gorog

Screening for venos thromboembolism in patient with COVID-19. (2021) Christophe Vandenbriele and Diana Gorog